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Purpose: Integrase inhibitor (INI)-containing regimens are increasingly replacing protease
inhibitor(PI)-containing regimens in clinical practice. The aim of this study was to evaluate
the determinants of the durability of INI-containing regimens after the switch.
Patients and methods: We retrospectively analysed all of the people with HIV infection
attending the University of Milan’s Infectious Diseases Unit at Luigi Sacco Hospital who
were switched from a PI- to an INI-containing regimen between April 2008 and March 2017.
The probability of remaining on an INI-containing regimen was estimated using Kaplan-
Meier curves, and the baseline clinical predictors of INI-containing regimen durability were
assessed using a multivariable Cox proportional hazard regression model.
Results: Three hundred and twelve patients were included in the analysis. The median time
of observation was 21 months (interquartile range 10–36 months). The main reasons for
switching from a PI-containing regimen to an INI-containing regimen were toxicities
(31.4%) and simpliﬁcation (31.1%). Univariate analysis revealed no difference in the prob-
ability of INI discontinuation between the patients treated with raltegravir, dolutegravir or
elvitegravir (p=0.060), but the multivariable Cox regression model showed that the patients
treated with dolutegravir were at less risk of discontinuation than those treated with ralte-
gravir (adjusted hazard ratio 0.49, 95% conﬁdence interval 0.26–0.95; p=0.034).
Conclusion: Switching from a PI- to an INI-containing regimen may be an option for
patients under virological control. The patients switched to dolutegravir were less likely to
discontinue the INI than those switched to raltegravir. Our ﬁndings support this therapeutic
strategy and highlight the durability and efﬁcacy of dolutegravir containing-regimens after
switching from a PI-containing regimen.
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Introduction
Combined antiretroviral therapy (cART) has dramatically changed the life expec-
tancy of people living with HIV by allowing the control of viral replication and thus
leading to a signiﬁcant reduction in HIV infection-related morbidity and mortality.1
However, toxicities associated with the use of the ﬁrst antiretroviral agents con-
siderably limited the universal and early use of cART for a number of years and
encouraged investigations into differences in the role of the various classes of
antiretroviral compounds.2,3
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Metabolic toxicity was detected as an untoward effect
of ﬁrst-generation antiretroviral agents very early in the
use of cART. Lipodystrophic syndrome and metabolic
abnormalities were found to be related to cumulative
exposure to thymidine analogues and protease inhibitors
(PI),4,5 and the ﬁndings of recent observational studies
have highlighted potential associations between integrase
inhibitors (particular dolutegravir [DTG]) and weight gain
and altered fat distribution.6–8 Boosted PIs have long been
the cornerstone of cART therapy, and still form the basis
of a substantial number of cART regimens. Before the
advent of integrase inhibitors (INIs), various strategies
were used to avoid ritonavir exposure in the subjects
who used unboosted atazanavir (ubATV) in order to
reduce metabolic toxicities,9 and new compounds (parti-
cularly INIs) are now progressively replacing boosted PIs
in both cART-naïve and cART-experienced patients.10
Initial trials highlighted an increased risk of cART
discontinuation due to virological failure in patients
switching from boosted lopinavir (LPV) to raltegravir
(RAL),11 but subsequent studies have shown that switch-
ing from boosted PIs to INI-containing regimens is viro-
logically effective and leads to improved metabolic
proﬁles.12,13 It has also been demonstrated that switching
from a boosted PI regimen to a single tablet regimen
(STR) containing boosted elvitegravir (EVG) can be effec-
tive and well tolerated,14 and that simplifying PI-contain-
ing to DTG-containing regimens is safe and effective,
particularly in patients aged >50 years and in those at
high cardiovascular risk.15,16 The STRIIVING study
showed no clear beneﬁt in terms of lipid proﬁles in
patients switched to DTG, but this may be partially
explained by the low cardiovascular risk of the study
patients and their different previous cART regimens,
which included PIs or non-nucleoside reverse transcriptase
inhibitors (NNRTIs).15 Furthermore, the NEAT022 study
revealed a clear beneﬁt in patients at high cardiovascular
risk who were switched to DTG from boosted PIs.16
Consequently, simpliﬁcation strategies involving a
switch from boosted PI-containing cART regimens to an
INI-containing regimen have now been introduced in rou-
tine clinical practice with the aim of reducing the long-
term toxicities caused by lifelong cART exposure.11–18
The aim of this study was to assess the durability and
metabolic impact of INI-containing regimens in a single-cen-
tre cohort of drug-experienced HIV-infected patients who had
previously been treated with a PI-containing regimen.
Materials and methods
We retrospectively analysed all of the HIV-infected
patients attending the University of Milan’s Infectious
Diseases Unit at Luigi Sacco Hospital who were switched
from a PI- to an INI-containing regimen between April
2008 and March 2017. Patients aged <18 years were
excluded from the analysis.
The demographic, epidemiologic and clinical data in
the patients’ clinical case ﬁles at the time of the switch
from a PI- to an INI-containing regimen and every six
months thereafter were anonymously entered in an ad hoc
electronic database.
The discontinuations of INI-containing regimens were
categorised as being due to virological failure (deﬁned as
two consecutive determinations of >50 HIV-RNA copies/
mL or one detection of >1000 HIV-RNA copies/mL),
toxicities, drug-drug interactions, simpliﬁcations, drop-
outs, deaths or other reasons. A change from one to
another INI-containing regimen was considered a failure
in the durability analysis, but the patients who only chan-
ged the drug formulation were not considered as failures.
The primary study end-point was the discontinuation of
the different INI-(RAL vs DTG)-containing regimens after
switching from a PI-containing regimen. The secondary
end-points were the durability of EVG vs RAL or DTG,
the probability of virological failure on the different INI-
containing regimens, the metabolic effects of switching
from a PI- to an INI-containing regimen, and the change
in 10-year cardiovascular risk as assessed by the
Framingham algorithm 12 months after the switch.
Sample size was calculated on the basis of the primary
end-point. It was estimated that a total of 272 participants
(136 per group) would provide a power of at least 80% to
exclude a non-inferiority margin of a 12.5% difference in the
proportion of participants reaching the primary endpoint,
assuming that treatment success was 90% among the patients
in the DTG group and a two-sided α of 0.05.12,16,17
The collected data were grouped into dichotomous and
continuous variables, and the patients were grouped on the
basis of their previous PI (boosted ATV, ubATV, boosted
darunavir [DRV], LPV, or boosted fosamprenavir [fAPV])
and its replacement INI (DTG, RAL or EVG).
The descriptive and inferential statistical analyses
assumed that an α of 0.05 was statistically signiﬁcant.
The probabilities of the discontinuation and virological
failure of the different INI-containing regimens after
switching from a PI-containing regimen were analysed
Giacomelli et al Dovepress
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by means of Kaplan-Meier curves. The baseline clinical
predictors of the durability and virological failure of the
INI-containing regimens were assessed using a multivari-
able Cox proportional hazard regression model, in which
the co-variates were age, gender, the number of previous
cART regimens, previous virological failure, initial PI,
backbone, >50 HIV-RNA copies/mL at the time of the
switch, CD4 cell count at the time of the switch, nadir
CD4 cell count, and HCV co-infection.
The variations in total cholesterol (TC), HDL choles-
terol and triglyceride (TG) levels were assessed using a
multivariable linear mixed effects regression model, and
the SAS PROC MIXED procedure with a random inter-
cept was used to correlate repeated measures. Intra-indivi-
dual variance was analysed using an autoregressive
correlation structure of the ﬁrst order, with TC, HDL
cholesterol and TG as the dependent variables, and age,
gender, baseline lipid values, statin use, concomitant teno-
fovir discontinuation, and initial PI as independent
variables.
Ten-year cardiovascular risk was assessed using the
Framingham algorithm at the time of the switch and
12 months after the switch from a PI- to INI-containing
regimen.19 The patients whose data were insufﬁcient for
the Framingham risk calculation and those who modiﬁed
their concomitant antiretroviral or non-antiretroviral treat-
ment (eg by introducing a statin) during the ﬁrst 12 months
after the switch were excluded from the analysis. A multi-
variable linear mixed effect regression model was used to
assess the predictors of the change in 10-year cardiovas-
cular risk 12 months after the switch. The co-variates
included in the ﬁnal model were age, gender, baseline
Framingham risk, and initial PI.
SAS version 9.4 software was used to make the statis-
tical analyses, and a p-value of <0.05 was considered
statistically signiﬁcant.
The study protocol was reviewed and approved by the
Comitato Etico Interaziendale Milano Area 1 (Ethics
Committee), and an informed consent form was signed
by all of the subjects who decided to participate in this
study.
Results
Table 1 shows the characteristics of the 312 patients
included in the analysis at the time of the switch from a
PI- to an INI-containing regimen. The patients treated with
RAL-containing regimens had been treated with a higher
median number of previous cART regimens than those
treated with DTG- or EVG-containing regimens (6, inter-
quartile range [IQR] 2–11 vs respectively 4, IQR 2–7 and
three, IQR 1–6; p=0.002), and included a greater propor-
tion of patients who had experienced a previous virologi-
cal failure (46, 34.1% vs respectively 22, 18% and 11,
20%; p=0.008) and patients switching with an HIV-RNA
count of >50 copies/mL (34, 25.2% vs respectively 13,
10.7% and 11, 20%; p=0.011). Moreover, in comparison
with those treated with DTG- or EVG-containing regi-
mens, the patients treated with RAL-containing regimens
were more frequently intravenous drug users (50, 37% vs
22, 18% and 3, 5.4%; p<0.0001) and had HCV co-infec-
tion (57, 42.2% vs 31, 25.4% and 9, 16.4%; p<0.001).
The median time of observation was 21 months (IQR 10–
36). The reasons for switching from a PI-containing regimen
to an INI-containing regimen were toxicities (31.4%) fol-
lowed by simpliﬁcation (31.1%), virological failure (18.6%),
drug-drug interactions (12.8%) and other reasons (6.1%).
Two hundred and ﬁfty-four patients switched to an INI-con-
taining regimen when their HIV-RNA count was <50 copies/
mL: 171 (67.3%) only changed the PI and 83 (32.7%) chan-
ged at least one other component of the regimen. Fifty-eight
patients switched when their HIV-RNA count was >50
copies/mL: 29 (50.0%) only changed the PI and the other
29 (50.0%) also changed another component of the regimen.
Fourteen (24.1%) of the patients with detectable viremia at
the time of the switch did not undergo an HIV resistance test
or the sample could not be ampliﬁed because of the low
viremia level; the results of the test in the remaining 44
patients (75.9%) were wild-type in 19 (43.2%), one major
mutation in one drug class (NRTI/NNRTI/PI) in 10 (22.7%),
at least one major mutation in two classes in 10 (22.7%), and
at least one major mutation in three classes in ﬁve (11.4%).
After combining the choice of INI-containing regimens and
the results of previous genotyping tests, 27 patients (61.4%)
were treated with a regimen containing three fully active
drugs, and 17 (38.6%) were treated with a regimen contain-
ing two fully active drugs.
Discontinuation rate
During the period of observation, 117 (37.5%) patients
discontinued their INI-containing regimen. The reasons
leading to discontinuation were simpliﬁcation (average
28.2%: 33.7% of RAL, 25% of DTG and 5.9% of EVG
discontinuations), virological failure (average 26.4%: 30%
of RAL, 5.0% of DTG and 35.3% of EVG discontinua-
tions), toxicities (average 15.4%: 8.7% of RAL, 35% of
DTG and 23.5% of EVG discontinuations), drop-outs
Dovepress Giacomelli et al
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(average 9.4%: 7.5% of RAL, 15% of DTG and 11.8% of
EVG discontinuations), deaths (average 7.7%: 5.1% of
RAL, 10% of DTG and 5.9% of EVG discontinuations),
drug-drug interactions (average 2.6%: 17.6% of EVG dis-
continuations), and other reasons (average 10.3%: 11% of
RAL and 10% of DTG discontinuations). Only 4.3% of
the INI discontinuations were due to neurological toxicity
(two in the RAL group and three in the DTG group).
Durability of INI-containing regimens
Figure 1 shows the durability of the different INI-contain-
ing regimens. Univariate analysis revealed no difference in
the probability of INI discontinuation between the patients
treated with RAL, DTG or EVG (p=0.060), but the risk of
discontinuation was lower in the case of STRs than in the
case of non-STRs (p=0.011). The probability of still being
on an INI-containing regimen after 12 months was 79.5%
(95% conﬁdence interval [CI] 72.6–86.4) in the case of
RAL, 87.5% (95% CI 81.3–93.7) in the case of DTG. and
87.8% (95% CI 78.5–95.1) in the case of EVG.
The multivariable Cox regression model (Table 2)
showed that the patients treated with DTG were at less
risk of discontinuation than those treated with RAL
(adjusted hazard ratio [aHR] 0.49, 95% CI 0.26–0.95;
p=0.038) as were the patients switching from ubATV in
comparison with those switching from boosted ATV (aHR
0.5, 95% CI 0.25–0.99; p=0.048)
Probability of virological failure on the
INI-containing regimens
The 12-month probability of not experiencing virological
failure on an INI-containing regimen was 92.2% (95% CI
87.2–97.1) in the case of RAL, 99% (95% CI 97.1–1.00)
in the case of DTG, and 97.1% (95% CI 92.8–1.00) in the
case of EVG.
Univariate analysis revealed a statistically signiﬁcant
difference in the risk of virological failure between the
three INIs (p=0.01) that was not conﬁrmed by the multi-
variable Cox regression model (Table 3). However, the
factors associated with an increased risk of virological
failure were a greater number of previous antiretroviral
regimens (aHR 1.12, 95% CI 1.00–1.24; p=0.046) and an
HIV-RNA count >50 copies/mL at the time of the switch
from a PI- to an INI-containing regimen (aHR 2.80, 95%
CI 1.22–6.45; p=0.015). A trend towards an increased risk
of virological failure was also observed in the case of male
gender (aHR 2.84; 95% CI 0.98–8.17; p=0.053).T
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Metabolic impact
Figure 2 shows the changes from baseline TC levels by
previous PI. Sixty-eight patients were being treated with
statins before the switch to an INI and ﬁve started on
statins during the study period; the 22 patients who dis-
continued statins during the study period (32.3%) were
excluded from the metabolic analysis.
Multivariate analysis revealed a correlation between
the changes in TC levels and the discontinuation of teno-
fovir disoproxil fumarate (TDF) at the time of the switch
from a PI- to an INI-containing regimen (estimate
9.52 mg/dL, standard error [SE] 2.75; p=0.0006), and
between TC levels and a previous antiretroviral regimen
containing boosted LPV (estimate −9.16 mg/dL, SE 3.43;
P
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0
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P=0.060
Months
RAL DTG EVG
24
Figure 1 Time dependent probability of INI-containing regimens discontinuation after switching from PI.
Note: No differences were observed in the three different INI (p=0.06).
Abbreviations: RAL, raltegravir; DTG, dolutegravir; EVG, elvitegravir.
Table 2 Multivariate Cox regression model of the continuance of INI-containing regimens after switching from PI
aHR IC 95% p value
Age (x 1 yrs more) 1.00 0.98–1.03 0.708
Previous cART regimens (x 1 more) 1.03 0.97–1.09 0.298
Previous VF 0.72 0.42–1.23 0.228
Male vs Female 1.17 0.71–1.95 0.533
ATVub vs ATV 0.50 0.25–0.99 0.048
DRV vs ATV 1.17 0.61–2.25 0.645
LPV vs ATV 0.73 0.41–1.32 0.302
fAPV vs ATV 0.87 0.43–1.75 0.701
DTG vs RAL 0.49 0.26–0.95 0.038
EVG vs RAL 0.57 0.27–1.20 0.140
TDF/FTC vs ABC/3TC 0.95 0.53–1.71 0.856
Other vs ABC/3TC 0.97 0.50–1.87 0.920
HIV-RNA > 50 cps/mL 1.02 0.60–1.74 0.941
CD4 > 500 cells/mmc 0.94 0.56–1.58 0.808
CD4 nadir < 200 cells/mmc 0.81 0.49–1.34 0.410
HCV coinfection 1.06 0.65–1.70 0.822
Abbreviations: aHR, adjusted hazard ratio; CI, conﬁdence interval; yrs, years; cART, combined antiretroviral therapy; cps, copies; ATV, boosted atazanavir; ATVub,
unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; TDF/FTC,
tenofovir disoproxil fumarate/emtricitabine; ABC/3TC, abacavir/lamivudine.
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p=0.008) and boosted fAPV (estimate −21.59 mg/dL, SE
4.34; p<0.0001) (Table 4).
Multivariate analysis also revealed a correlation
between the change from baseline TG levels and previous
exposure to boosted LPV (estimate −32.94 mg/dL, SE
13.23; p=0.013) and boosted fAPV (estimate −36.81 mg/
dL, SE 17.02; p=0.031) (Table 5).
Only female gender was associated with the changes in
HDL cholesterol levels in the multivariate model (estimate
1.82 mg/dL, SE 0.69; p=0.009).
Ten-year cardiovascular risk was assessed in 172
patients using the Framingham algorithm. There was no
difference between the risk calculated at the time of the
switch from a PI- to an INI-containing regimen and the
risk calculated 12 months later (8.5%, IQR 4.5–19.1 vs
8.8%, IQR 4.3–18; p=0.836). After correcting for the pre-
vious PI, statin use, TDF discontinuation at the time of the
switch, and a high baseline 10-year cardiovascular risk
(>10%), the factors associated with risk modiﬁcation In
the multivariable model were age (estimate 0.04%, SE
0.02; p=0.038) and baseline cardiovascular risk (estimate
0.94%, SE 0.01; p<0.0001).
Discussion
The ﬁndings of this study of a single-centre cohort of HIV-
positive, antiretroviral- experienced patients suggest that
switching from a PI- to an INI-containing regimen is safe,
long-lasting, and leads to a signiﬁcant improvement in
metabolic proﬁles.
The overall rate of INI discontinuation due to all
causes was comparable with that reported in other cohort
studies.13 Initial concerns were raised during the post-
marketing use of DTG because the incidence of adverse
neuropsychiatric events was higher than that observed in
clinical trials.20,21 Our ﬁnding that discontinuations due to
neurological toxicity accounted for 4.3% of all disconti-
nuations would seen to allay such concerns, which could
lead to unnecessary discontinuation.22,23
Approximately one-third of the patients in our cohort
changed their PI-containing regimen because of the occur-
rence of cART-related toxicity, and 18.6% of the patients
were in a condition of virological failure at the time of the
switch to an INI-containing regimen. It is well known that
the use of INI in patients with a long antiretroviral history
and previous virological failures may predispose to an
increased risk of INI discontinuation due to virological
inefﬁcacy when a regimen with a low genetic barrier is
used (ie RAL or EVG).11,24 At the time of the switch, the
failing patients received two or three active drugs in
respectively 38.6% and 61.4% of cases, and none of the
patients received only one active drug on the basis of the
interpretation of historical genotypes. The patients treated
with RAL had a longer history of previous therapy, and a
history of intravenous drug use and HCV co-infection, all
of which frequently characterise the patients who received
Table 3 Multivariate Cox regression model of the probability of virological failure of INI-containing regimens after switching from PI
aHR IC 95% p value
Age (x 1 yrs more) 1.01 0.97–1.05 0.725
Previous cART regimens (x 1 more) 1.12 1.00–1.24 0.046
Previous VF 1.89 0.74–4,78 0.181
Male vs Female 2.84 0.98–8,17 0.053
ATVub vs ATV 0.63 0.18–2.24 0.473
DRV vs ATV 2.71 0.77–9.57 0.121
LPV vs ATV 1.17 0.39–3.52 0.783
fAPV vs ATV 1.12 0.32–3.96 0.859
DTG vs RAL 0.17 0.02–1.52 0.113
EVG vs RAL 0.92 0.28–3.06 0.898
TDF/FTC vs ABC/3TC 2.87 0.62–13.25 0.176
Other vs ABC/3TC 1.85 0.41–8.46 0.425
HIV-RNA > 50 cp/mL 2.80 1.22–6.45 0.015
CD4 > 500 cells/mmc 0.90 0.32–2.57 0.851
CD4 nadir < 200 cells/mmc 0.44 0.15–1.30 0.138
HCV coinfection 1.01 0.39–2.58 0.986
Abbreviations: aHR, adjusted hazard ratio; CI, conﬁdence interval; yrs, years; cART, combined antiretroviral therapy; cps, copies; ATV, boosted atazanavir; ATVub,
unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted fosamprenavir; DTG, dolutegravir; RAL, raltegravir; EVG, elvitegravir; TDF/FTC,
tenofovir disoproxil fumarate/emtricitabine; ABC/3TC, abacavir/lamivudine.
Dovepress Giacomelli et al
Drug Design, Development and Therapy 2019:13 submit your manuscript | www.dovepress.com
DovePress
2277
 
D
ru
g 
De
sig
n,
 D
ev
el
op
m
en
t a
nd
 T
he
ra
py
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
15
9.
14
9.
73
.1
04
 o
n 
10
-J
ul
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
220
200
180
C
ho
le
st
er
ol
 _
lo
t (
m
ea
n)
160
BL
BL
195 (5)
177 (6)
191 (4)
205 (6)
207 (8)
189 (6)
188 (7)
185 (5)
185 (7)
177 (7)
187 (7)
178 (8)
184 (7)
183 (6)
167 (11)
6 mesl 12 mesl
ATV, mean mg/dl (SE)
DRV, mean mg/dl (SE)
LPV, mean mg/dl (SE)
fAPV, mean mg/dl (SE)
ATVub, mean mg/dl (SE)
6m
PI ATV ATVub DRV LPV fAPV
Time
12m
Figure 2 Median TC levels from the time of the switch and after 6 and 12 months according to the PI of provenience.
Note: TC levels are expressed in mg/dL.
Abbreviations: tot, total; BL, baseline; m, months; ATV, boosted atazanavir; ATVub, unboosted atazanavir; DRV, boosted darunavir; fAPV, boosted fosamprenavir; LPV,
boosted lopinavir.
Table 4 multivariable linearmixed effects regressionmodel for the variation of total cholesterol after the switch from a PI- to an INI-containing
regimen
Estimate
mg/dL
SE p value
Female vs male 4.26 2.26 0.061
Age (x one yrs more) 0.07 0.10 0.502
Baseline cholesterol (x 1 unit more) 0.80 0.02 <0.0001
Statins utilization yes vs no –4.13 2.42 0.089
Concomitant TDF interruption 9.52 2.75 0.0006
Time* –1.66 2.25 0.461
*ATVub vs ATV 6.52 3.42 0.057
*DRV vs ATV –0.35 3.55 0.920
*LPV vs ATV –9.16 3.43 0.008
*fAPV vs ATV –21.59 4.34 <0.0001
Note: *The estimates refer to parameters associated to the interaction between PIs and the time unit inserted in the model which is 6 months.
Abbreviations: SE, standard error; yrs, years; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted
fosamprenavir; TDF, tenofovir disoproxil fumarato; PIs, protease inhibitors; INI, integrase inhibitors.
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the ﬁrst INI available for clinical use, and may be asso-
ciated with a reduced probability of cART adherence and
shorter duration of the current regimen.25,26 They also
presented a higher rate of uncontrolled HIV viremia at
the time of the switch than the patients treated with DTG
or EVG, and were thus in suboptimal condition for switch-
ing to a low genetic barrier regimen.11,24 Finally, more
than one-third of the patients who discontinued a RAL-
containing regimen did so for reasons of simpliﬁcation,
and it is likely that the advent of drugs to be administered
once a day and the reduced pill burden affected the dur-
ability of the RAL-containing regimens.27,28 All of these
factors may partially explain the difference in the durabil-
ity of the DTG- and RAL-containing regimens.
Another factor potentially inﬂuencing the greater dur-
ability of DTG-containing regimens is the possibility of
using DTG in an STR as the patients on an STR were less
likely to discontinue an INI-containing regimen than those
receiving multiple tablets.29
Our univariate analysis showed that there was an
increased risk of virological failure in the patients who
switched to RAL than those who switched to DTG.
Moreover, approximately one third of the RAL- and
EVG-containing regimens were discontinued due to viro-
logical failure. However, the signiﬁcant difference
between regimens was lost in the multivariate model,
which showed that an increased risk of virlogical failure
was associated with uncontrolled HIV-RNA at the time of
the switch and a greater number of previous antiretroviral
regimens. All of these factors are known to be associated
with an increased risk of virological failure in patients on
low genetic barrier cART.11,30,31 A trend towards an
increased risk of virological failure (albeit of borderline
statistical signiﬁcance) was observed in the case of males,
which conﬂicts with some published data indicating a
greater risk among females.32
In terms of metabolic proﬁles, there was a favourable
association with a reduction in TC levels in patients coming
from boosted LPV- and boosted fAPV-containing regimens.
This conﬁrms the ﬁndings of previous studies showing an
improvement in metabolic proﬁles after switch from a
boosted PI to an INI.12,30 Accordingly, there was also a
favourable association between post-switch TG levels and
previous exposure to boosted LPV and boosted fAPV.16,33
HDL cholesterol levels were not associated with previous PI
use, but higher levels were associated with female gender.34
It is known that females have higher HDL cholesterol levels
than males, which has a cardioprotective function especially
in the pre-menopausal period, but the gender-related reasons
for the difference in HDL levels are not fully understood.35
There was a signiﬁcant increase in TC levels in the
patients who discontinued TDF at the same time as they
switched from a PI- to an INI-containing regimen, thus
conﬁrming previous ﬁndings showing that TDF has a
statin-like effect that is unmasked when it is
discontinued.36,37
An association between weight gain and a switch to
INI-containing regimens has been postulated,6–8 but a
recent report based on the SCOLTA observational cohort
did not provide any evidence of a relationship between
INIs and weight gain, and it has been shown cabotegravir
does not have this effect.38–40 Nevertheless, this potential
side effect of INI-containing regimens should be consid-
ered and balanced against their potential advantage.
Table 5 multivariable linear mixed effects regression model for the variation of triglycerides levels after the switch from a PI- to an
INI-containing regimen
Estimate mg/dL SE p value
Female vs male –6.0 8.50 0.475
Age (x one yrs more) –0.25 0.37 0.499
Baseline triglycerides (x 1 unit more) 0.61 0.02 <0.0001
Statins utilization yes vs no 15.75 9.26 0.093
Concomitant TDF interruption 4.95 10.05 0.622
Time* –10.62 8.76 0.226
*ATVub vs ATV 2.90 13.26 0.826
*DRV vs ATV –2.77 13.68 0.839
*LPV vs ATV –32.94 13.23 0.013
*fAPV vs ATV –36.81 17.02 0.031
Note: *The estimates refer to parameters associated to the interaction between PIs and the time unit inserted in the model which is 6 months.
Abbreviations: SE, standard error; yrs, years; ATV, boosted atazanavir; ATVub, unboosted Atazanavir; DRV, boosted darunavir; LPV, boosted lopinavir; fAPV, boosted
fosamprenavir; TDF, tenofovir disoproxil fumarato; PIs, protease inhibitors; INI, integrase inhibitors.
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Approximately one-third of the patients in our cohort had
HCV co-infection and 24% were intravenous drug users, and
a higher percentage of both switched to RAL. The advent of
direct antiviral agents (DAAs) has prompted switching from
PI- to INI-containing regimens as INIs have fewer drug-to-
drug interactions, and RAL is the INI that potentially has
fewer drug-to-drug interactions with DAAs.41
The use of ubATV in order to avoid the untoward
metabolic effects of the ritonavir booster was once wide-
spread, particularly in Italy, but this strategy has now been
replaced by new INI-containing simpliﬁcation strategies
that have been demonstrated to be safe in elderly patients
at high cardiovascular risk.16,42,43 The switch from ubATV
to an INI-containing regimen led to greater durability
(albeit of borderline statistical signiﬁcance) than a switch
to boosted ATV. This may have been partially due to the
large number of patients switched for reasons of simpliﬁ-
cation or toxicity in this sub-group of patients.
Approximately one-quarter of the patients in our cohort
were taking lipid-lowering statins at the time of the switch.
This percentage is higher than that found in previous
studies, which have shown the under-prescription of sta-
tins to people living with HIV, but in line with the results
of a recent study by Gatell et al involving patients at high
cardiovascular risk or who were older than ﬁfty years.16,44
However, approximately one-third of our patients discon-
tinued lipid-lowering treatment during the study period.
We did not observe any improvement in 10-year cardi-
ovascular risk as assessed using the Framingham algorithm
12 months after the switch from a PI- to an INI-containing
regimen. This is in line with the results of a recent study by
Taramasso et al, who found that switching from a boosted
PI- or efavirenz-containing regimen to an INI- or rilpivir-
ine-containing regimen did not reduce cardiovascular risk
as assessed by the Framingham algorithm despite a signiﬁ-
cant improvement in lipid proﬁles.45 However, it must be
remembered that this way of assessing cardiovascular risk
does not take into account the potential impact of the com-
ponents of the antiretroviral regimen as some antiretroviral
agents (eg abacavir and PIs) have been associated with
increased cardiovascular risk, although it is likely that the
effect of antiretroviral treatment is more marginal than the
classic cardiovascular risk factors. Moreover, it has been
shown that antiretroviral agents only affect the risk of
patients at higher risk.46,47 Taken together with those of
previously published studies, our ﬁndings suggest that mod-
ifying cART has a limited impact on the cardiovascular risk
calculated using the Framingham score, and highlight the
importance of concentrating on classic modiﬁable cardio-
vascular risk factors.
This study has a number of limitations. First of all, its
retrospective design exposes it to potential errors due to
omissions or the lack of data in clinical case ﬁles.
Secondly, its single-centre nature limits the applicability
of the results to different settings. Thirdly, the choice of
switching from a PI- to an INI-containing regimen was not
controlled but based on the clinical judgement of indivi-
dual physicians. Finally, and as discussed above, the
patients treated with RAL had a longer previous antiretro-
viral history than those treated with DTG or EVG, were
exposed to a heterogeneous series of antiretroviral regi-
mens, and were more likely to be co-infected with HCV.
Conclusion
On the basis of our ﬁndings, switching from a PI- to an
INI-containing regimen can be considered a valid option
for patients under virological control. However, the viro-
logical efﬁcacy of the regimens may be affected by the
number of previous antiretroviral regimens in a patient’s
history. DTG-containing regimens seem to be more dur-
able than RAL-containing regimens probably because
DTG can be used in a once-daily STR. Patients previously
treated with boosted LPV and boosted fAPV showed a
signiﬁcant improvement in lipid proﬁles. However, as
there was no reduction in cardiovascular risk after the
switch, it seems that modifying cART is not enough by
itself and so attempts to modify classic cardiovascular risk
factors should be continued.
Abbreviation list
PI, protease inhibitor; NNRTI, non-nucleoside reverse
transcriptase inhibitor; INI, integrase inhibitor; RAL, ral-
tegravir; EVG, elvitegravir; DTG, dolutegravir; ub,
unboosted; LPV, lopinavir; fAPV, fosamprenavir; ATV,
atazanavir; DRV, darunavir; IQR, interquartile range; CI,
conﬁdence interval; cART, combined antiretroviral ther-
apy; STR, single tablet regimen; TC, total cholesterol; TG,
triglycerides; DAA, direct antiviral agents.
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